Forest Cuts Combunox Detailing Following Disappointing Launch
This article was originally published in The Pink Sheet Daily
Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.
You may also be interested in...
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue